HONG KONG SAR - EQS Newswire - 27 March 2026 - A fully integrated biopharmaceutical company – Uni-Bio Science Group Limited ("Uni-Bio Science", together with its subsidiaries referred to as the "Group", stock code: 0690.HK), is pleased to announce its annual results for the year ended 31 December 2025 (the "Year"). Key Accomplishments in 2025 During the Year, the Group achieved a spectrum of accomplishments, for both of its marketed products and innovative biologics. The key highlights include:

1. During the Year, the Group delivered record-breaking financial results, with revenue recorded a 6.0% year-on-year ("YoY") increase, reaching approximately HK$586.2 million. Profit for the year soared by 12.7% YoY to approximately HK$93.3 million, and net profit margin increased by 1.0 percentage points YoY to 15.9%, marking a historic high. The earnings per share reached approximately HK$1.56 cents, reflecting a growth of 15.5% YoY or a CAGR of 18.55% from 2023 to 2025.
2. The Group generated solid cash from operations in the Year, operating cash flow and free cash flow increased by 32.7% and 27.3% YoY, respectively. Cash ratio increased from 0.53 times at the end of 2024 to 1.63 times at the end of 2025. The cash conversion cycle improved from 124 days to 107 days, highlighting greater operating efficiency. Backed by sustainable earnings and a healthy cash flow, the board of directors ("Board") has declared a dividend payment for 2025 of HK$0.313 cents per share.
3. Since its official launch in March 2024, Bogutai^® has sustained strong growth momentum, driven by a solid commercialization strategy and successful academic engagement. In 2025, Bogutai^® demonstrated rapid market adoption in China, achieving a remarkable year-on-year revenue growth of 111.0%.
4. In May 2025, the Group's second ophthalmology product, 金因康^® (Diquafosol Sodium Eye Drops), received marketing approval from the China National Medical Products Administration ("NMPA"), marking a significant milestone in expanding the Group's ophthalmic portfolio following GeneSoft^®. The Group is actively preparing its launch and marketing strategy. In addition to leveraging synergy with GeneSoft^® and its established online and offline distribution network for rapid market penetration, 金因康^® will specifically target the mid-to-high-end segment of dry eye patients outside the hospital setting, those who prioritize long-term efficacy and premium product quality.
5. In June 2025, the Group officially launched the high-end series GeneQueens^® of 肌顏態^® and the medical device brand 金因敷^®, marking two key milestones in its strategic expansion into the integrated"Drug, Medical Device, and Aesthetics"field. These product launches reflect the Group's commitment to enhancing its skin health product matrix and addressing evolving consumer needs for efficacy-driven, medical-grade skincare in both functional skincare and post-aesthetic recovery.
6. In July 2025, the marketing application of Isavuconazonium sulfate capsules were officially accepted by the NMPA. Isavuconazonium sulfate capsules are expected to be approved for launch as early as the fourth quarter of 2026, offering a safer, more effective, and high-quality treatment option for patients suffering from invasive fungal infections.
7. In 2025, the Group established a strategic partnership with Wenzhou Medical University to explore a thermosensitive gel formulation combining EGF and bFGF, leveraging the university's proven expertise in bFGF production. As a key growth factor in regenerative medicine, bFGF is highly effective in promoting granulation and angiogenesis.
8. Towards the end of 2025, the Group repositioned its long-term strategy from "Stable Growth" to "Innovation-Driven," signifying a bold transformation from an integrated pharmaceutical company into a global pioneer in regenerative medicine. The Group is advancing a transformative R&D strategy spanning four key areas: muscular-skeletal regeneration, skin regeneration, ocular regeneration, and ENT regeneration.

Annual Results For 2025, the Group recorded a revenue of approximately HK$586.2 million, representing an increase of 6.0% YoY. Revenue from Bogutai^® increased from approximately HK$ $63.5 million to approximately HK$ 134.0 million, representing a significant increase of 111.0%. Revenue generated from GeneTime^® was approximately HK$220.4 million, representing an increase of 10.9% YoY. GeneSoft^® recorded a 7.9% YoY decrease in revenue from approximately HK$41.9 million to approximately HK$38.6 million due to intense market competition. Pinup^® recorded a decrease of...